Cargando…
Reduction of therapeutic antibody self-association using yeast-display selections and machine learning
Self-association governs the viscosity and solubility of therapeutic antibodies in high-concentration formulations used for subcutaneous delivery, yet it is difficult to reliably identify candidates with low self-association during antibody discovery and early-stage optimization. Here, we report a h...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704398/ https://www.ncbi.nlm.nih.gov/pubmed/36433737 http://dx.doi.org/10.1080/19420862.2022.2146629 |
_version_ | 1784840046552023040 |
---|---|
author | Makowski, Emily K. Chen, Hongwei Lambert, Matthew Bennett, Eric M. Eschmann, Nicole S. Zhang, Yulei Zupancic, Jennifer M. Desai, Alec A. Smith, Matthew D. Lou, Wenjia Fernando, Amendra Tully, Timothy Gallo, Christopher J. Lin, Laura Tessier, Peter M. |
author_facet | Makowski, Emily K. Chen, Hongwei Lambert, Matthew Bennett, Eric M. Eschmann, Nicole S. Zhang, Yulei Zupancic, Jennifer M. Desai, Alec A. Smith, Matthew D. Lou, Wenjia Fernando, Amendra Tully, Timothy Gallo, Christopher J. Lin, Laura Tessier, Peter M. |
author_sort | Makowski, Emily K. |
collection | PubMed |
description | Self-association governs the viscosity and solubility of therapeutic antibodies in high-concentration formulations used for subcutaneous delivery, yet it is difficult to reliably identify candidates with low self-association during antibody discovery and early-stage optimization. Here, we report a high-throughput protein engineering method for rapidly identifying antibody candidates with both low self-association and high affinity. We find that conjugating quantum dots to IgGs that strongly self-associate (pH 7.4, PBS), such as lenzilumab and bococizumab, results in immunoconjugates that are highly sensitive for detecting other high self-association antibodies. Moreover, these conjugates can be used to rapidly enrich yeast-displayed bococizumab sub-libraries for variants with low levels of immunoconjugate binding. Deep sequencing and machine learning analysis of the enriched bococizumab libraries, along with similar library analysis for antibody affinity, enabled identification of extremely rare variants with co-optimized levels of low self-association and high affinity. This analysis revealed that co-optimizing bococizumab is difficult because most high-affinity variants possess positively charged variable domains and most low self-association variants possess negatively charged variable domains. Moreover, negatively charged mutations in the heavy chain CDR2 of bococizumab, adjacent to its paratope, were effective at reducing self-association without reducing affinity. Interestingly, most of the bococizumab variants with reduced self-association also displayed improved folding stability and reduced nonspecific binding, revealing that this approach may be particularly useful for identifying antibody candidates with attractive combinations of drug-like properties. Abbreviations: AC-SINS: affinity-capture self-interaction nanoparticle spectroscopy; CDR: complementarity-determining region; CS-SINS: charge-stabilized self-interaction nanoparticle spectroscopy; FACS: fluorescence-activated cell sorting; Fab: fragment antigen binding; Fv: fragment variable; IgG: immunoglobulin; QD: quantum dot; PBS: phosphate-buffered saline; V(H): variable heavy; V(L): variable light. |
format | Online Article Text |
id | pubmed-9704398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-97043982023-02-07 Reduction of therapeutic antibody self-association using yeast-display selections and machine learning Makowski, Emily K. Chen, Hongwei Lambert, Matthew Bennett, Eric M. Eschmann, Nicole S. Zhang, Yulei Zupancic, Jennifer M. Desai, Alec A. Smith, Matthew D. Lou, Wenjia Fernando, Amendra Tully, Timothy Gallo, Christopher J. Lin, Laura Tessier, Peter M. MAbs Report Self-association governs the viscosity and solubility of therapeutic antibodies in high-concentration formulations used for subcutaneous delivery, yet it is difficult to reliably identify candidates with low self-association during antibody discovery and early-stage optimization. Here, we report a high-throughput protein engineering method for rapidly identifying antibody candidates with both low self-association and high affinity. We find that conjugating quantum dots to IgGs that strongly self-associate (pH 7.4, PBS), such as lenzilumab and bococizumab, results in immunoconjugates that are highly sensitive for detecting other high self-association antibodies. Moreover, these conjugates can be used to rapidly enrich yeast-displayed bococizumab sub-libraries for variants with low levels of immunoconjugate binding. Deep sequencing and machine learning analysis of the enriched bococizumab libraries, along with similar library analysis for antibody affinity, enabled identification of extremely rare variants with co-optimized levels of low self-association and high affinity. This analysis revealed that co-optimizing bococizumab is difficult because most high-affinity variants possess positively charged variable domains and most low self-association variants possess negatively charged variable domains. Moreover, negatively charged mutations in the heavy chain CDR2 of bococizumab, adjacent to its paratope, were effective at reducing self-association without reducing affinity. Interestingly, most of the bococizumab variants with reduced self-association also displayed improved folding stability and reduced nonspecific binding, revealing that this approach may be particularly useful for identifying antibody candidates with attractive combinations of drug-like properties. Abbreviations: AC-SINS: affinity-capture self-interaction nanoparticle spectroscopy; CDR: complementarity-determining region; CS-SINS: charge-stabilized self-interaction nanoparticle spectroscopy; FACS: fluorescence-activated cell sorting; Fab: fragment antigen binding; Fv: fragment variable; IgG: immunoglobulin; QD: quantum dot; PBS: phosphate-buffered saline; V(H): variable heavy; V(L): variable light. Taylor & Francis 2022-11-26 /pmc/articles/PMC9704398/ /pubmed/36433737 http://dx.doi.org/10.1080/19420862.2022.2146629 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Report Makowski, Emily K. Chen, Hongwei Lambert, Matthew Bennett, Eric M. Eschmann, Nicole S. Zhang, Yulei Zupancic, Jennifer M. Desai, Alec A. Smith, Matthew D. Lou, Wenjia Fernando, Amendra Tully, Timothy Gallo, Christopher J. Lin, Laura Tessier, Peter M. Reduction of therapeutic antibody self-association using yeast-display selections and machine learning |
title | Reduction of therapeutic antibody self-association using yeast-display selections and machine learning |
title_full | Reduction of therapeutic antibody self-association using yeast-display selections and machine learning |
title_fullStr | Reduction of therapeutic antibody self-association using yeast-display selections and machine learning |
title_full_unstemmed | Reduction of therapeutic antibody self-association using yeast-display selections and machine learning |
title_short | Reduction of therapeutic antibody self-association using yeast-display selections and machine learning |
title_sort | reduction of therapeutic antibody self-association using yeast-display selections and machine learning |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704398/ https://www.ncbi.nlm.nih.gov/pubmed/36433737 http://dx.doi.org/10.1080/19420862.2022.2146629 |
work_keys_str_mv | AT makowskiemilyk reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT chenhongwei reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT lambertmatthew reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT bennettericm reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT eschmannnicoles reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT zhangyulei reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT zupancicjenniferm reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT desaialeca reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT smithmatthewd reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT louwenjia reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT fernandoamendra reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT tullytimothy reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT gallochristopherj reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT linlaura reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning AT tessierpeterm reductionoftherapeuticantibodyselfassociationusingyeastdisplayselectionsandmachinelearning |